Here are four updates from gastroenterology companies from the past week:
The Royal Court of Jersey sanctioned Shire's proposed acquisition of Takeda Pharmaceuticals.
Exact Sciences expects to post fourth quarter 2018 revenues between $142.5 million to $143.5 million, a 64 percent year-over-year increase.
EnteraSense secured $4 million in funding for its gastrointestinal tract bleed-detecting capsule.
Landos Biopharma reported results from its phase 1 trial of BT-11, an ulcerative colitis and Crohn's disease treatment.